Is NCT03159403 results overdue?

Yes — results are overdue. Primary completion was 2018-02-15; the FDAAA-801 reporting deadline (2019-02-15) passed 2729 days ago and no results are posted on ClinicalTrials.gov.

A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting

NCT ID	NCT03159403 ↗
Sponsor	Melinta Therapeutics, Inc. (INDUSTRY)
Phase	—
Status	COMPLETED
Primary completion	2018-02-15 (ACTUAL)
Reporting deadline	2019-02-15 (completion + 365d)
Days overdue	2729
Results posted	No — check results tab ↗
FDA-regulated	drug: yes, device: no
Provenance	Flagged overdue on 2026-06-21 · SHA-256 `530e2d11aa43a45e…` (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT03159403. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.